Two Cases of Acute Exacerbation of Interstitial Pneumonia Treated with Polymyxin B-immobilized Fiber Column Hemoperfusion Treatment

The effect of polymixin B-immobilized fiber column (PMX) hemoperfusion treatment for acute exacerbation of interstitial pneumonia (IP) has been reported. Here, we report 2 cases of acute exacerbation of IP successfully treated with PMX hemoperfusion. One is a 55-year-old woman who was diagnosed as m...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Internal Medicine 2007, Vol.46(17), pp.1447-1454
Hauptverfasser:	Noma, Satoshi, Matsuyama, Wataru, Mitsuyama, Hideo, Suetsugu, Takayuki, Koreeda, Yoshimizu, Mizuno, Keiko, Higashimoto, Ikkou, Kakihana, Yasuyuki, Hashiguchi, Teruto, Maruyama, Ikuro, Osame, Mitsuhiro, Arimura, Kimiyoshi
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-Bacterial Agents - therapeutic use Bronchoalveolar Lavage Fluid bronchoalveolar lavage fluid cells CD18+/CD11c Fatal Outcome Female Hemoperfusion - methods high mobility group box-1 (HMGB-1) Humans Lung Diseases, Interstitial - complications Lung Diseases, Interstitial - therapy Male Middle Aged Polymyxin B - therapeutic use Respiratory Insufficiency - etiology Respiratory Insufficiency - therapy Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The effect of polymixin B-immobilized fiber column (PMX) hemoperfusion treatment for acute exacerbation of interstitial pneumonia (IP) has been reported. Here, we report 2 cases of acute exacerbation of IP successfully treated with PMX hemoperfusion. One is a 55-year-old woman who was diagnosed as microscopic polyangiitis (MPA) with IP. The other is a 58-year-old man, diagnosed as having idiopathic pulmonary fibrosis. Both cases were treated with PMX hemoperfusion and other therapies. One died on day 44 and the other is still alive. The PMX hemoperfusion treatment decreased the serum levels of several cytokines and activated neutrophil percentage in bronchoalveolar lavage fluid.
ISSN:	0918-2918 1349-7235
DOI:	10.2169/internalmedicine.46.0117